Comparative Pharmacology
Head-to-head clinical analysis: ILOSONE versus TAO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILOSONE versus TAO.
ILOSONE vs TAO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin (ILOSONE) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis by blocking translocation.
Troleandomycin (TAO) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide chain elongation.
Erythromycin (Ilosone) base or stearate: 250-500 mg orally every 6 hours. Estolate: 250-500 mg orally every 6 hours. Maximum dose 4 g/day.
250-500 mg orally every 6 hours or 500 mg intravenously every 6 hours. For severe infections, up to 500 mg every 6 hours IV.
None Documented
None Documented
1.5-2 hours in adults; prolonged in hepatic impairment (up to 5-6 hours)
Terminal elimination half-life of 12-24 hours in adults; may be prolonged in hepatic impairment (up to 40-60 hours) and in neonates (2-5 days).
Renal (2-5% unchanged), biliary/fecal (majority, >90% as metabolites and unchanged drug)
Primarily hepatic metabolism with <10% excreted unchanged in urine; approximately 30% excreted in feces via bile.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic